HRYZ-T102

N/A

Report date: 2025/12/04 20:00:08

Base Information

Drug NameHRYZ-T102
Drug Alias NameHRYZ-T102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionAlpha-fetoprotein modulatorsHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators
TargetsAlpha-fetoproteinHLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHengrui Yuanzheng (Shanghai) Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHengrui Yuanzheng (Shanghai) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A